Exclusive Summary

• Comprehensive portfolio: Offering both 2ml (first-line emergency antiarrhythmic) and 20ml/30ml (pharmacological stress agent for CAD diagnostics), capturing two major resilient department needs.
• Strong clinical necessity and guideline endorsement: Included in the WHO Essential Medicines List and heavily recommended by AHA/ACC/ESC guidelines as the first-line therapy for SVT, guaranteeing stable baseline hospital demand.
• Supply chain stability with high margins: Sterile injectables face frequent shortages globally; leveraging cost-effective Chinese manufacturing ensures reliable supply while offering robust profit margins for local distributors in medical tenders.